Novartis Issues Safety Guidelines for Gilenya
Novartis Pharmaceuticals Canada Inc. issued new safety recommendations regarding the risk of serious heart-related side effects associated with the use of its multiple sclerosis drug Gilenya (fingolimod). The Canadian Press reports that the safety recommendations follow reports that some users of the drug suffered from heart-related side effects, including temporary but serious irregular heartbeat, within hours